経肺薬剤送達システム：各種技術と世界の市場

世界の経肺薬剤送達システムの市場規模は、2022年の574億米ドルから、2027年には769億米ドルに達し、2022年から2027年の予測期間中は6.0％のCAGRで成長すると予測されています。

定量吸入器の部門は、2022年の257億米ドルから、2027年には344億米ドルに達し、2022年から2027年の予測期間中は6.0%のCAGRで成長すると予測されています。また、ドライパウダー吸入器の部門は、2022年の225億米ドルから、2027年には306億米ドルに達し、6.3％のCAGRで成長すると予測されています。

当レポートでは、世界の経肺薬剤送達システムの市場を調査し、市場概要、市場成長への各種影響因子の分析、技術動向、関連法規制、市場規模の推移・予測、各種区分・地域/主要国別の詳細分析、競合環境、主要企業のプロファイルなどをまとめています。

目次

第1章 イントロダクション

第2章 サマリー・ハイライト

第3章 市場力学・技術の背景

• 市場の定義と概要
• 肺の状態と治療
• 市場促進要因・動向
• 市場抑制要因
• 市場機会
• 法規制

第4章 市場内訳：経肺薬剤送達システム別

• 吸入技術の概要
• ドライパウダー吸入器 (DPI)
  • 概要
  • 上市済み製品
• 定量吸入器 (MDI)
  • 概要
  • 上市済み製品
• ネブライザー
  • 概要
  • 上市済み製品の概要：製造業者別

第5章 COVID-19の影響

第6章 使用中の経肺薬剤送達システム

• 吸入治療薬
  • ステロイド
  • 気管支拡張薬

第7章 市場内訳：疾患領域別

• 喘息
  • 喘息発作
  • 喘息・肥満
  • 死亡率
  • 疾患分類
  • 診断
  • 治療・治療薬
  • 市場規模・予測
• 慢性閉塞性肺疾患 (COPD)
  • 診断
  • 治療・治療薬
  • 市場規模・予測
• その他の病気
  • 市場規模・予測

第8章 市場内訳：地域別

• 北米
• 欧州
• アジア太平洋
• その他の地域
• 南米

第9章 特許分析

第10章 企業プロファイル

• 3M
• ABBOTT LABORATORIES
• ASTRAZENECA
• BOEHRINGER INGELHEIM GMBH
• CIPLA
• DR. REDDY'S LABORATORIES LTD.
• GLAXOSMITHKLINE PLC
• PHILIPS RESPIRONICS
• LUPIN
• MYLAN N.V.
• MERCK KGAA
• NOVARTIS AG
• OMRON CORP.
• PFIZER INC.
• PULMATRIX INC.
• TEVA PHARMACEUTICALS INDUSTRIES LTD.

第11章 付録：略語

List of Tables

• Summary Table A : Global Market for Pulmonary Drug Delivery Systems, by Type, Through 2027
• Summary Table B : Global Market for Pulmonary Drug Delivery Systems, by Region, Through 2027
• Table 1 : Key Products Going Off-Patent, 2020-2030
• Table 2 : Inhaler Device Characteristics
• Table 3 : Global Market for Pulmonary Drug Delivery Systems, by Type, Through 2027
• Table 4 : Capsule-based Inhaler Devices
• Table 5 : Blister-based Inhaler Devices
• Table 6 : Reservoir/Cartridge-based Inhaler Devices
• Table 7 : MDIs, HFA Propellant
• Table 8 : MDIs, Anti-Inflammatory Medicine
• Table 9 : MDIs, Combination Medicine
• Table 10 : Commonly Used MDIs
• Table 11 : Comparison of Nebulizers
• Table 12 : Marketed Nebulizers by Manufacturer
• Table 13 : Total Number of COVID-19 Confirmed Cases and Deaths, by Region, June 2022
• Table 14 : COVID-19 Confirmed Cases and Deaths Globally, by Country, June 20, 2022
• Table 15 : Inhaled Steroids
• Table 16 : Inhaled Corticosteroids
• Table 17 : Inhaled Corticosteroids, Combination Inhalers
• Table 18 : Short-Acting Inhaled Beta-Agonist (SABA) Bronchodilators
• Table 19 : Short-Acting Inhaled Muscarinic Antagonist (SAMA) and SABA Combination Bronchodilators
• Table 20 : Long-Acting Inhaled Beta-2 Agonists (LABA) Bronchodilators
• Table 21 : Long-Acting Inhaled Muscarinic Antagonists (LAMA) Bronchodilators
• Table 22 : LABA and LAMA Combination Bronchodilators
• Table 23 : Global Asthma Market, Through 2027
• Table 24 : Leading Causes of Death Worldwide, 2020
• Table 25 : Global COPD Market, Through 2027
• Table 26 : Global Market for Other Pulmonary Diseases, Through 2022
• Table 27 : Prevalence of Asthma, by Race and Ethnicity in Americans
• Table 28 : European Self-Reported Asthma, 2020
• Table 29 : European Self-Reported COPD, 2020
• Table 30 : Leading Causes of Death in Australia, 2020 and 2021
• Table 31 : Key Patents, Pulmonary Drug Delivery Systems
• Table 32 : 3M: Key Developments
• Table 33 : Abbott: Product Portfolio by Business Segment, 2021
• Table 34 : Abbott: Key Developments
• Table 35 : AstraZeneca PLC: Key Developments
• Table 36 : Royal Philips: List of Subsidiaries
• Table 37 : Philips Health: Business Segments
• Table 38 : Lupin: Key Developments
• Table 39 : Novartis AG: Key Developments
• Table 40 : Pfizer Inc.: Key Developments
• Table 41 : Teva: Key Developments
• Table 42 : Abbreviations Used in Pulmonary Drug Delivery Systems

List of Figures

• Summary Figure : Global Market for Pulmonary Drug Delivery Systems, by Type, 2019-2027
• Figure 1 : Smoking in Adults, by Region, 2020
• Figure 2 : Global Market for Pulmonary Drug Delivery Systems, by Type, 2019-2027
• Figure 3 : Non-Communicable Disease Mortality Share, by Cause of Death, 2021
• Figure 4 : Global Asthma Market, 2019-2027
• Figure 5 : Global COPD Market, 2019-2027
• Figure 6 : Global Market for Other Pulmonary Diseases, 2019-2027
• Figure 7 : North American Pulmonary Drug Delivery Systems Market, 2019-2027
• Figure 8 : Health Issues in the Mexican Population, Proportional Mortality, 2020
• Figure 9 : Annual Mortality Rate for Asthma, by Country, 2020
• Figure 10 : European Pulmonary Drug Delivery Systems Market, 2019-2027
• Figure 11 : U.K. Mortality, by Disease 2021
• Figure 12 : Leading Causes of Death in Italy, Percentage Change, 2020
• Figure 13 : Leading Causes of Death in Rest of Europe Region, 2021
• Figure 14 : Asia-Pacific Pulmonary Drug Delivery Systems Market, 2019-2027
• Figure 15 : Annual Mortality Rates in Middle East and Africa, by Disease, 2020
• Figure 16 : Rest of the World Pulmonary Drug Delivery Systems Market, 2019-2027
• Figure 17 : Abbott: Annual Revenue, 2018-2021
• Figure 18 : Abbott: Revenue Share, by Segment, 2021
• Figure 19 : AstraZeneca PLC: Annual Revenue, 2018-2020
• Figure 20 : AstraZeneca PLC: Revenue Share, by Therapy Areas, 2020
• Figure 21 : Dr. Reddy's Laboratories Ltd.: Annual Revenue, 2018-2020
• Figure 22 : Dr. Reddy's Laboratories Ltd.: Revenue Share, by Business Segment, 2020
• Figure 23 : GlaxoSmithKline PLC: Annual Revenue, 2018-2020
• Figure 24 : GlaxoSmithKline PLC: Revenue Share, by Business Segment, 2020
• Figure 25 : Lupin: Annual Revenue, 2018-2020
• Figure 26 : Merck KGaA: Annual Revenue, 2018-2020
• Figure 27 : Merck KGaA: Revenue Share, by Business Segment, 2020
• Figure 28 : Novartis AG: Annual Revenue, 2018-2020
• Figure 29 : Novartis AG: Revenue Share, by Division, 2020
• Figure 30 : Pfizer Inc.: Annual Revenue, 2018-2020
• Figure 31 : Teva: Annual Revenue, 2018-2020

Highlights:

The global pulmonary drug delivery systems market should reach $76.9 billion by 2027 from $57.4 billion in 2022 at a compound annual growth rate (CAGR) of 6.0% for the forecast period of 2022 to 2027.

Metered dose inhalers segment of the global pulmonary drug delivery systems market is expected to grow from $25.7 billion in 2022 to $34.4 billion in 2027 at a CAGR of 6.0% for the forecast period of 2022 to 2027.

Dry powder inhalers segment of the global pulmonary drug delivery systems market is expected to grow from $22.5 billion in 2022 to $30.6 billion in 2027 at a CAGR of 6.3% for the forecast period of 2022 to 2027.

Report Scope:

This report will provide a detailed look at the pulmonary drug delivery systems market, highlighting major pulmonary diseases with detailed epidemiology for major disease areas such as asthma, COPD and cystic fibrosis. The report includes an industry-wide assessment of the novel products, launches, recent approvals, R&D pipeline and blockbuster drugs.

In the report, the regulatory scenario of pulmonary drug delivery systems is discussed for each device type. This will include products approved by regulatory authorities in recent years. Products under development or in different stages of clinical trials are also analyzed.

The report includes profiles of major companies in the market for pulmonary drug delivery systems, with overviews of their key product offerings and financials.

Report Includes:

• 44 tables
• A brief overview and up-to-date analysis of the global markets for pulmonary drug delivery systems
• Analyses of the global market trends, with historic market revenue data from 2019 to 2021, estimates for 2022, and projections of compound annual growth rates (CAGRs) through 2027
• Estimation of the actual market size and revenue forecast for pulmonary drug delivery systems in USD value terms, and their corresponding market share analysis by type of drug delivery systems, application/disease area and region
• Highlights of the major pulmonary diseases with detailed epidemiology for major disease areas such as asthma, COPD and cystic fibrosis; also, an industry-wide assessment of the key developments, novel products, recent approvals, R&D activities, pipeline products and blockbuster drugs
• In-depth information (facts and figures) concerning market drivers, opportunities and challenges, and other macroeconomic forces affecting the global pulmonary drug delivery systems market
• Holistic review of the international regulatory landscape for pulmonary drug delivery systems with emphasis on recently approved products as well as products under development or in different stages of clinical trials
• Updated information on key mergers and acquisition deals, agreements, collaborations and other impactful strategies adopted by key players in the global pulmonary drug delivery systems market
• Assessment of the recent patents published and granted on pulmonary drug delivery systems and related technologies
• Identification of the major stakeholders and analysis of the competitive landscape based on recent developments and segmental revenues
• Descriptive company profiles of the market leading players, including Abbott, Dr. Reddy's Laboratories Ltd., GlaxoSmithKline PLC, Lupin and Pfizer Inc.

Table of Contents

Chapter 1 Introduction

• 1.1 Study Goals and Objectives
• 1.2 Reasons for Doing This Study
• 1.3 What's New in This Update?
• 1.4 Scope of Report
• 1.5 Information Sources
  • 1.5.1 Secondary Research
  • 1.5.2 Primary Research
• 1.6 Methodology
• 1.7 Geographic Breakdown
• 1.8 Analyst's Credentials
• 1.9 BCC Custom Research
• 1.10 Related BCC Research Reports

Chapter 2 Summary and Highlights

Chapter 3 Market Dynamics and Technology Background

• 3.1 Market Definition and Overview
  • 3.1.1 Mechanism of Action
  • 3.1.2 Advantages
  • 3.1.3 Limitations/Challenges
• 3.2 Pulmonary Conditions and Therapies
  • 3.2.1 Introduction to the Respiratory System
• 3.3 Market Drivers and Trends
  • 3.3.1 Improved Patient Compliance and Ease of Use
  • 3.3.2 Cost Pressures on Countries
  • 3.3.3 Rising Incidence of Asthma
  • 3.3.4 Causes
  • 3.3.5 Reducing the Burden of Asthma
• 3.4 Market Restraints
  • 3.4.1 Competition from Generics on the Rise
• 3.5 Market Opportunities
  • 3.5.1 Introduction of Smart Nebulizers
• 3.6 Regulation and Legislation
  • 3.6.1 U.S.

Chapter 4 Market Breakdown by Pulmonary Drug Delivery Systems

• 4.1 Overview of Inhalation Techniques
• 4.2 Dry Powder Inhalers (DPIs)
  • 4.2.1 Overview
  • 4.2.2 Marketed Products
• 4.3 Metered Dose Inhalers (MDIs)
  • 4.3.1 Overview
  • 4.3.2 Marketed Products
• 4.4 Nebulizers
  • 4.4.1 Overview
  • 4.4.2 Marketed Products Overview by Manufacturer

Chapter 5 COVID-19 Impact

• 5.1 Overview
• 5.2 COVID-19 Crisis
• 5.3 Impact on Market for Pulmonary Drug Delivery Systems
• 5.4 Current Outlook

Chapter 6 Pulmonary Drug Delivery Systems in Use

• 6.1 Therapeutic Agents Administered via Inhalation
  • 6.1.1 Steroids
  • 6.1.2 Bronchodilators

Chapter 7 Market Breakdown by Disease Area

• 7.1 Introduction
• 7.2 Asthma
  • 7.2.1 Asthma Attacks
  • 7.2.2 Asthma and Obesity
  • 7.2.3 Mortality
  • 7.2.4 Disease Classification
  • 7.2.5 Diagnosis
  • 7.2.6 Treatment and Therapies
  • 7.2.7 Market Size and Forecasts
• 7.3 Chronic Obstructive Pulmonary Disease (COPD)
  • 7.3.1 Diagnosis
  • 7.3.2 Treatment and Therapies
  • 7.3.3 Market Size and Forecasts
• 7.4 Other Diseases
  • 7.4.1 Market Size and Forecasts

Chapter 8 Market Breakdown by Region

• 8.1 North America
  • 8.1.1 U.S.
  • 8.1.2 Canada
  • 8.1.3 Mexico
• 8.2 Europe
  • 8.2.1 Germany
  • 8.2.2 U.K.
  • 8.2.3 France
  • 8.2.4 Italy
  • 8.2.5 Spain
  • 8.2.6 Rest of Europe
• 8.3 Asia-Pacific
  • 8.3.1 China
  • 8.3.2 Japan
  • 8.3.3 India
  • 8.3.4 South Korea
  • 8.3.5 Rest of Asia-Pacific
• 8.4 Rest of the World
• 8.5 South America

Chapter 9 Patent Analysis

• 9.1 Overview

Chapter 10 Company Profiles

• 3M
• ABBOTT LABORATORIES
• ASTRAZENECA
• BOEHRINGER INGELHEIM GMBH
• CIPLA
• DR. REDDY'S LABORATORIES LTD.
• GLAXOSMITHKLINE PLC
• PHILIPS RESPIRONICS
• LUPIN
• MYLAN N.V.
• MERCK KGAA
• NOVARTIS AG
• OMRON CORP.
• PFIZER INC.
• PULMATRIX INC.
• TEVA PHARMACEUTICALS INDUSTRIES LTD.

Chapter 11 Appendix: Abbreviations